Genetic Technologies announces the Company has established a precision oncology division and announced its highly anticipated portfolio of new diagnostic tests under its geneType precision oncology brand. The proprietary-developed tests will provide invaluable information to medical oncologists, helping determine which therapies will have the most efficacious impact in treating a range of cancers including melanoma, lung, pancreatic, colorectal, breast, ovarian and brain cancers. Huge market opportunity for this advanced portfolio of methylation, mutation and liquid biopsy tests. Earlier detection of a range of cancers leads to significantly improved patient outcomes. These new tests will transform oncology diagnostics, companion diagnostics, and disease monitoring. A guideline-driven approach for reimbursement makes tests accessible and affordable for patients.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GENE:
- Genetic Technologies Unveils Breakthrough Oncology Tests
- Genetic clinicians’ adoption growing, sales up 5-fold year-over-year
- Genetic Technologies Innovates Breast Cancer Screening
- Genetic Technologies to pilot GeneType in Breast Screen centers across U.S.
- Genetic Technologies Advances Women’s Health Literacy
